Point-of-Care Molecular Diagnostics Market Intelligence: Size, Share and Growth Outlook Through 2036

Market Overview

Market Size and Outlook

• The point-of-care molecular diagnostics market was valued at USD 5.3 billion in 2025 and is set to reach USD 5.8 billion by 2026-end.
• The market is forecast to grow at a CAGR of 10.0% between 2026-2036 to reach USD 15.1 billion by 2036.
• The market is expected to be worth USD 5.8 Bn in 2026 and is expected to reach USD 15.1 Bn by 2036, growing at a CAGR of 10.0%.
• Assays and Kits will dominate with a 52.7% share, while Real Time Polymerase Chain Reaction will lead with a 64.2% share.
• The USD 9.3 Bn incremental opportunity from 2026 to 2036 speaks to clinical adoption, regulatory compliance cycles and geographic expansion of procurement.

Demand and Growth Drivers

• Respiratory Diseases and Sexually Transmitted Diseases applications are expected to sustain procurement of assays and kits as clinical protocols tighten and patient populations expand through 2036.
• Real Time Polymerase Chain Reaction and isothermal nucleic acid amplification are projected to shape procurement patterns, with regulatory-approved formats capturing the largest volume share.
• Japan at 10.3% and USA at 10.2% are the fastest-growing markets, reflecting expanding institutional infrastructure and policy-driven adoption.
• Sustained procurement is being created for assays and kits for Respiratory Diseases, Sexually Transmitted Diseases, and Hospital Acquired Infections applications.

Analyst Perspective

• Brevintel analysis indicates companies that combine regulatory approval breadth with clinical evidence portfolios are expected to strengthen institutional procurement positions.
• Cancer and Oncology Assays is projected to gain share as genetic mutation detection and tumor marker panels expand.
• Isothermal nucleic acid amplification is gaining popularity in certain applications alongside RT-PCR.

Market Dynamics

Drivers, Restraints, and Opportunities

• Japan is driving growth at 10.3% driven by PMDA approval pathways, aging population demographics and hospital automation investment.
• USA at 10.2% reflects FDA regulatory pathway maturity, Medicare reimbursement structures, and high per-capita assays and kits utilization rates in hospital and ambulatory settings.
• Demand is aimed at Respiratory Disease Assays, Influenza Testing Kits and Coronavirus Detection Kits, each targeting different respiratory disease needs.
• Genetic Mutation Detection and Tumor Marker Panels are gaining traction as procurement diversifies.

Supply and Pricing Dynamics

• Abbott Laboratories and Cepheid (Danaher Corporation) lead through regulatory approval breadth, clinical evidence portfolios, and institutional procurement contracts.
• Buyers compare assay menu breadth, time-to-result, and reimbursement alignment when awarding hospital and ambulatory contracts.
• Regulatory-approved formats capture the largest volume share as clinical protocols tighten.

Segmentation Analysis

Product Outlook

• Assays and Kits will dominate with a 52.7% share, supported by recurring consumable demand in respiratory and STI testing.
• Cancer and Oncology Assays is viewed as a secondary growth category as genetic mutation detection and tumor marker panels gain traction.

Technology Outlook

• Real Time Polymerase Chain Reaction is expected to account for 64.2% of the technology segment in 2026.
• By technology, Real Time Polymerase Chain Reaction at 64.2% leads demand, reflecting a preference over isothermal nucleic acid amplification.
• RT-PCR is supported by Respiratory Disease Assays, Influenza Testing Kits, and Coronavirus Detection Kits in clinical and diagnostic settings.

Regional Outlook

Japan

• Japan is projected to lead growth at 10.3% through 2036, driven by PMDA approval pathways, aging population demographics, and hospital automation investment.

USA

• USA at 10.2% reflects FDA regulatory pathway maturity, Medicare reimbursement structures, and high per-capita assays and kits utilization in hospital and ambulatory settings.

Competitive Landscape

Overview

• Abbott Laboratories and Cepheid (Danaher Corporation) lead the competitive field through regulatory approval breadth, clinical evidence portfolios, and institutional procurement contracts.
• bioMérieux SA, Roche Diagnostics, and QuidelOrtho Corporation compete through installed instrument bases and assay menus.
• Visby Medical, Sherlock Biosciences, Mammoth Biosciences, Biomeme, Detect Inc., and Scope Fluidics target decentralized and rapid molecular formats.

Key Players

Integrated Producers

• Abbott Laboratories
• Cepheid (Danaher Corporation)
• Roche Diagnostics
• bioMérieux SA
• QuidelOrtho Corporation

Specialty Suppliers

• Visby Medical
• Sherlock Biosciences
• Mammoth Biosciences
• Biomeme
• Detect Inc.
• Scope Fluidics